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Abstract: The objectives of this study were to evaluate the reliability of wearable inertial motion unit 18 
(IMU) sensors in measuring spinal range of motion under supervised and unsupervised conditions 19 
in both laboratory and ambulatory settings. A secondary aim of the study was to evaluate the 20 
reliability of composite IMU metrology scores (IMU-ASMI (Amb)). Forty people with axSpA 21 
participated in this clinical measurement study. Participant spinal mobility was assessed by 22 
conventional metrology (Bath Ankylosing Spondylitis Metrology Index, linear version – BASMILin) 23 
and by a wireless IMU sensor-based system which measured lumbar flexion-extension, lateral 24 
flexion and rotation. Each sensor-based movement test was converted to a normalized index and 25 
used to calculate IMU-ASMI (Amb) scores. Test-retest reliability was evaluated using intra-class 26 
correlation coefficients (ICC). There was good to excellent agreement for all spinal range of 27 
movements (ICC > 0.85) and IMU-ASMI (Amb) scores (ICC > 0.87) across all conditions. Correlations 28 
between IMU-ASMI (Amb) scores and conventional metrology were strong (Pearson correlation ≥ 29 
0.85). An IMU sensor-based system is a reliable way of measuring spinal lumbar mobility in axSpA 30 
under supervised and unsupervised conditions. While not a replacement for established clinical 31 
measures, composite IMU-ASMI (Amb) scores may be reliably used as a proxy measure of spinal 32 
mobility.   33 
Keywords: axial spondyloarthritis; spinal mobility; inertial measurement unit; reliability 34 
 35 
1. Introduction 36 
Axial spondyloarthritis (axSpA) is a complex chronic inflammatory disease predominantly 37 
affecting the axial skeleton [1]. In the early stages of the disease, restriction in spinal mobility is mainly 38 
due to reversible inflammation in and around the spine, but in later stages the restriction becomes 39 
permanent due to structural bony damage [2-3]. Monitoring of individuals with axSpA should center 40 
on aspects of the disease that cause symptoms or functional disability [4], and which are subject to 41 
change as the disease progresses or treatment is introduced, such as decreased spinal mobility [5-6]. 42 
Spinal mobility has been recognized as an important outcome in the management of axSpA and 43 
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clinical assessment in axSpA [6-7]. The Bath Ankylosing Spondylitis Metrology Index (BASMI) is a 50 
well-established method of measuring spinal movement in axSpA [8]. While the BASMI is a low-cost 51 
tool with minimal training and equipment required, it cannot be performed independently, limiting 52 
its utility outside of the clinical setting. It also lacks the sensitivity to change required to monitor 53 
disease progression [9-11]. As a result of these concerns, the BASMI failed to achieve approval by the 54 
ASAS group as a core outcome measure in axSpA [5]. There is a rapidly growing role for telemedicine 55 
as a tool to improve care for individuals with rheumatic disease, although there is a recognition that 56 
limitations in technology need to be understood and addressed to achieve standards of care 57 
consistent with existing in-person services [12]. There is therefore a need for a reliable and sensitive 58 
measure of spinal mobility to be used in studies of drug and physical interventions in axSpA. 59 
Video-based optoelectronic systems are often thought of as the laboratory gold standard for 60 
human motion analysis [13-14]. These systems can provide complex descriptions of body segment 61 
motion but only measure movement over a short period of time.  Their capture area can be limited 62 
by cameras, body markers and (environmental) equipment positioning, and they create artificial 63 
environments for movement assessment. Due to the high cost of equipment and training, they are 64 
therefore not feasible for many research centers or real-world testing. 65 
In recent years, wearable inertial motion unit (IMU) sensor systems have advanced to the point 66 
of offering a viable method of clinically measuring spinal mobility [13-14] and analyzing spinal 67 
posture [15]. An IMU sensor typically incorporates a tri-axial accelerometer, gyroscope and 68 
magnetometer, and several can be incorporated unobtrusively as part of a wearable sensor system. 69 
Validity and reliability of such systems in the measurement of lumbar spine mobility has been 70 
established in healthy populations [16-17]. The validity and reliability of an IMU sensor-based system 71 
for evaluating cervical and lumbar spinal mobility in individuals with axSpA were recently 72 
established under supervised conditions [18-19]. If the full range of spinal mobility can be reliably 73 
measured in unsupervised ambulatory settings using IMU sensor-based systems, this tool could 74 
provide a viable method of reducing variability in measurement of spinal mobility, be sensitive to 75 
small changes in mobility over time, and be an important step towards digital self-management. It 76 
could be used by individuals with axSpA and clinicians involved in their care to reliably monitor 77 
signs remotely, providing clinicians with a “real-life” assessment of current disease state.  78 
This study is the third in a project [18, 19] investigating wearable IMU sensors and composite 79 
metrology scores in individuals with axSpA, with a focus on reliability in the ambulatory setting. The 80 
primary aim of this study was to assess the reliability of spinal IMU sensors in measuring spinal 81 
mobility of individuals with axSpA. The objectives were to evaluate the reliability of spinal IMU 82 
sensors in measuring spinal range of motion 1) under supervised and unsupervised conditions in the 83 
exercise laboratory, and 2) under unsupervised conditions in an ambulatory setting. A secondary aim 84 
of the study was to evaluate the reliability of calculated composite IMU metrology scores (IMU-ASMI 85 
(Amb)) and to establish correlations with BASMI. The reader is advised to refer to Gardiner et al. [19], 86 
Aranda-Valera et al. [18], and to the supplementary material for a detailed explanation of the IMU-87 
ASMI (Amb) score.  88 
2. Materials and Methods 89 
2.1. Study Design  90 
This was a clinical measurement study with a specific focus on reliability. The study was 91 
approved by the local research ethics committee [REC Reference: 2017-10 List 37 (20)]. 92 
2.2. Participant Eligibility & Recruitment  93 
Inclusion criteria for the study were as follows: diagnosis of axSpA (by ASAS criteria) made at 94 
least six months prior to recruitment to the study, age between 18 years and 80 years old and the 95 
ability to read and understand the English language. Exclusion criteria were severe joint or spinal 96 
pain at the time of the study, prior total hip arthroplasty or severely restricted hip movement, history 97 
of previous vertebral fracture, history of previous spinal surgery, severe scoliosis, spinal deformity 98 
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or complete segmental fusion of the spine, pregnancy or being unable to mobilize without assistance 100 
or mobility aid. 101 
Participant selection was through convenience sampling. Potential participants attending a 102 
dedicated hospital-based axSpA clinic were informed of the study by a gatekeeper who was not part 103 
of the research team. Notice of the study was also circulated via the social media channels of the 104 
Ankylosing Spondylitis Association of Ireland and Arthritis Ireland, and sent to individuals who 105 
were on a register having expressed interest in taking part in research projects. Interested persons 106 
contacted the study team and were screened for eligibility over the phone or via email. Participant 107 
diagnosis was confirmed by letter from the participant’s rheumatologist or general practitioner. 108 
2.3. Data Collection and Baseline Assessments 109 
Socio-demographic (age, sex and employment status) and anthropometric (weight, height and 110 
BMI) data were collected. Condition-specific data (time since onset of symptoms, time since 111 
diagnosis, medications and HLA-B27 status) were self-reported by participants. A battery of clinical 112 
questionnaires were self-completed by participants. These were: the Bath Ankylosing Spondylitis 113 
Disease Activity Index (BASDAI) [20], the Bath Ankylosing Spondylitis Functional Index (BASFI) 114 
[21], the Bath Ankylosing Spondylitis Global Score (BAS-G) [22], and the Ankylosing Spondylitis 115 
Quality of Life questionnaire (ASQoL) [23]. 116 
The ViMoveTM wireless sensor kit (DorsaViTM, Melbourne, Australia) was used as an IMU sensor-117 
based system to measure spinal range of movement. Members of the research team attended a half-118 
day training course to ensure that sensor application and movement tests were carried out according 119 
to the manufacturer’s standardized protocols. The ViMove system uses two IMU sensors to provide 120 
an absolute orientation estimation (roll, pitch, and yaw) and calculate the relative orientation in three 121 
planes (sagittal, frontal and transverse) by combining the measurements of both sensors. The sensors 122 
connect and transmit IMU data using radio frequency to a pocket recording device at a frequency of 123 
20 Hz, from which data can be downloaded or viewed directly from a laptop (see Figure 1). The 124 
ViMove sensor setup was previously validated against both the Fastrak and Vicon motion sensor 125 
systems [17, 24]. Aranda-Valera et al [18] recently established the validity of the sensor setup in 126 
evaluating spinal mobility in an individual with axSpA using an optical motion capture system as a 127 
reference. 128 
 129 
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Figure 1. (a) ViMove sensor location; (b) Pocket recording device used by participant 152 
2.4. Assessment Schedule 153 
Eligible participants attended the test center for assessment on two consecutive days. A research 154 
physiotherapist (MOG) trained in assessing individuals with axSpA carried out clinical tests. Both 155 
assessments were at approximately the same time each day. The phase between the two 156 
appointments in the laboratory was a community-based ambulatory phase, during which 157 
participants were unsupervised. Table 1 summarizes the testing schedule. 158 
Table 1. Study assessment schedule 159 
 Day 1 - Laboratory Ambulatory Phase Day 2 - Laboratory 
Baseline data collection ✓ -- -- 
BASMILin & chest expansion ✓ -- ✓ 
Pain NRS & Fatigue NRS ✓ ✓ ✓ 






BASMILin: Bath Ankylosing Spondylitis Metrology Index (linear version); NRS: numeric rating scale 160 
On Day 1, socio-demographic data were recorded and anthropometric measurements were 161 
completed. Following a five minute warm-up (treadmill walking or stationary exercise bike 162 
depending on participant preference), chest expansion and spinal mobility using the linear versions 163 
of the Bath Ankylosing Spondylitis Metrology Index (BASMILin) were recorded following ASAS 164 
guidelines [6, 25-26]. 165 
The two sensors were then attached to the participant according to the manufacturer’s 166 
guidelines. The lower (sacral) sensor was positioned using a line drawn between the posterior 167 
superior iliac spines, and the upper lumbar (trunk) sensor was positioned above this line using 168 
DorsaViTM designed height-specific templates to ensure the accurate positioning of the upper sensor 169 
over the T12 vertebra (see Fig. 1). Both sensors were mounted into a baseplate attached to an adhesive 170 
strip, which was placed directly on the skin. Calibration of the system was performed in relaxed 171 
standing (as per manufacturer’s standardized protocol) and angles were recorded at the zero position 172 
for each IMU sensor to set the baseline position. Each sensor then calculated orientation angles with 173 
respect to this calibrated starting position. 174 
Using standardized instructions, the assessor verbally guided the participants through a 175 
sequence of spinal movements: flexion, extension, lateral flexion (left then right), and rotation (left 176 
then right). Each movement was repeated three times before moving to the next movement 177 
(Condition 1: laboratory, supervised). Participants were then instructed to repeat the same sequence 178 
of spinal movements without supervision (Condition 2: laboratory, unsupervised). Participants 179 
followed either an instructional video (an example is included in the supplementary material) or 180 
written instructions (depending on preference); the same standardized instructions were used as 181 
during the supervised tests. The assessor left the room until all movements in the sequence were 182 
completed. Participants were instructed to press an ‘event’ button on the wireless pocket recorder 183 
when they were about to begin each movement, and again when they had completed the movement. 184 
Participants left the exercise laboratory with the two IMU sensors in situ. During this ambulatory 185 
phase, participants repeated the spinal movement sequence at home by following video or written 186 
instructions and pressing the ‘event’ button on the wireless recorder (Condition 3: Ambulatory, 187 
unsupervised). The following day, participants returned to the exercise laboratory. The BASMILin and 188 
the same spinal movements were repeated under supervised and unsupervised conditions. As test 189 
sessions were at different times of day, the diurnal variation in symptoms was monitored by 190 
participants recording their levels of pain and fatigue on a numerical rating scale (Pain NRS from ‘0 191 
- No pain’ to ’10 - Most severe’ and Fatigue NRS from ‘0 - None’ to ‘10 - Very severe’) prior to and 192 
after completing the spinal movements [27]. 193 
2.5. Data Management 194 
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2.5.1. Sensor Data Output 195 
Data was downloaded from sensors after each phase of testing using Microsoft Excel for 196 
Windows version 2009 (Microsoft Corporation, Washington, USA). The start and end of movement 197 
tests were identified using ‘event’ markers, and minimum and maximum degrees of movement were 198 
generated within each set of event markers. The data analyst visually inspected each movement test, 199 
and adjusted the start and end of the movement window if needed, to ensure they coincided with 200 
actual spinal movement. Each movement was repeated three times, and the maximum degree of 201 
movement was computed from the available repetitions (see Section 3.2). The mean of these degree 202 
of movement values was used in subsequent calculations.  Output for rotation movements was only 203 
available under supervised conditions owing to technical limitations with the system. Output was 204 
designated as Trunk (from the upper sensor, the orientation angle from the upper lumbar sensor to 205 
the ground; represents lumbar and pelvic movement) and Lumbar (the angle between the upper 206 
lumbar sensor and the sacral sensor; represents lumbar movement ). The ‘full-arc’ range of movement 207 
for a given spinal movement test was calculated. The reliability of full-arc movements has been 208 
shown to be higher than measurements from midline [19]. 209 
Minimum, maximum and range data were independendly validated by examining the raw IMU 210 
sensor data for each test. A random selection of n=5 participant data samples (12.5% of all samples) 211 
were analysed using Microsoft Excel. The event markers corresponding with the start and end of each 212 
spinal movement test were again visually analysed by an independent reviewer (JC), and Excel-213 
generated data values for each movement were numerically compared with the corresponding values 214 
generated by the ViMove software for each movement test. Results showed that there were no 215 
discrepancies between data generated by both methods for day 1 and day 2 of laboratory data. There 216 
was a comparison variation of 1.09 degrees within all ambulatory data samples. This was considered 217 
an acceptable amount of variation.  218 
2.5.2. Calculation of composite metrology score (IMU-ASMI (Amb)) 219 
Normalized scales permit rapid evaluation of mobility, without the need for clinicians to know 220 
normal ranges of movement. Each sensor-based movement test (Flexion-Extension, Lateral Flexion 221 
L+R, and Rotation L+R) was converted into a normalized index using a formula based on that used 222 
to calculate BASMILin [26]. The 10th and 90th percentile ranges for each sensor-based movement test 223 
were obtained from research cohorts associated with this research group (Cordoba healthy controls, 224 
Altnagelvin AxSpA cohort). Normalized scores were calculated as follows: ((90𝑡ℎ 𝑐𝑒𝑛𝑡𝑖𝑙𝑒 −225 
 𝐴) / (90𝑡ℎ 𝑐𝑒𝑛𝑡𝑖𝑙𝑒 −  10𝑡ℎ 𝑐𝑒𝑛𝑡𝑖𝑙𝑒)) / 10); A = range of motion in degrees). If A ≥ 90th centile, the 226 
normalized score = 0; if A ≤ 10th centile, the normalized score = 10. Composite IMU-ASMI (Amb) 227 
scores were calculated for the lumbopelvic region (Trunk-ASMI) and the lumbar region (Lumbar-228 
ASMI). Trunk-ASMI and Lumbar-ASMI were calculated as the mean of the normalized scores of the 229 
lumbopelvic region and lumbar region, respectively. The reliability of regional composite indices has 230 
been shown to be superior to that of individual components [19]. The reader is advised to refer to the 231 
supplementary material for a detailed explanation of the IMU-ASMI composite metrology score. 232 
2.6. Statistical Methods 233 
Descriptive data are presented as frequencies and percentages for categorical variables, and 234 
continuous data were presented as mean and standard deviation, or median and interquartile range, 235 
as appropriate.  236 
Test-retest reliability, compared across laboratory conditions (supervised and unsupervised) 237 
and ambulatory conditions, was evaluated using intra-class correlation coefficient (ICC) and 238 
standard error of measurement (SEM). Two-way, mixed-effects, single rater, absolute agreement 239 
model for ICCs were used. ICC interpretation was as follows: <0.5 = poor, 0.5 to 0.75 = moderate, 0.75 240 
and 0.9 = good, > 0.90 = excellent [28]. The SEM was calculated as follows: SEM=SD × √(1-ICC), with 241 
SD representing the pooled (two measurements) SD of the measure. Agreement between movement 242 
tests under each condition was evaluated using Bland-Altman analysis. The mean bias and the limits 243 
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of agreement (LoA) were calculated to provide an estimate of the interval in which 95% of the 257 
differences between both test conditions are. 258 
Correlations between BASMIlin and IMU-ASMI (Amb) scores under laboratory and ambulatory 259 
conditions were evaluated by Pearson correlation, which were interpreted as follows: values between 260 
0.1 and 0.69 denoted weak to moderate correlation, values above 0.7 were regarded as a strong 261 
correlation [29]. Friedman’s test, with post-hoc Wilcoxon Signed-rank tests, were used to evaluate the 262 
change in pain and fatigue NRS scores across test sessions. SPSS for Windows version 26 (IBM, New 263 
York, USA), MedCalc version 19.5.1 (MedCalc Software, Ostend, Belgium) and Microsoft Excel for 264 
Windows version 2013 (Microsoft Corporation, Washington, USA) were used for analysis. 265 
3. Results 266 
3.1. Recruitment and Participant Characteristics 267 
Forty eligible participants were recruited to the study and completed the protocol between April 268 
2018 and December 2018. Figure 2 illustrates the participant recruitment to the study. Twenty-five 269 
participants were male and 15 were female. Mean age of participants was 48.0 years (range 27 to 76) 270 
and mean symptom duration was 23.6 years (range 3 to 52). A range of disease severity is seen in the 271 
scores across clinical measures. Sixty-five percent of the participants were taking anti-TNFα 272 
medication. Participant baseline characteristics are summarized in Table 2. 273 
 274 
 275 
Figure 2. Participant recruitment 276 
Table 2. Descriptive characteristics of study participants 277 
Variable AxSpA Cohort (n = 40) 
Age, years 48.0 (12.9); [27 – 76] 
Sex (male/female), n 25 / 15 
Symptom duration, years 23.6 (13.7); [3 – 52]  
Time since diagnosis, years 9.0 (26.5)*; [0-43] 
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Employed, n (%) 23 (57.5)  
BASMILin†  
Lateral lumbar flexion 
Tragus to wall distance 
Modified Schober’s test 
Intermalleolar distance 
Cervical rotation 
3.8 (1.8); [1.2 – 7.9] 
4.9 (2.5); [0 – 9.0] 
2.4 (2.0); [0.5 – 7.6] 
5.4 (2.5); [0 – 9.7] 
3.1 (1.9) ;[0 – 7.0] 
3.3 (2.2); [0.3 – 9.5] 
Chest expansion, cm 2.47 (2.2); [0.6 – 13.2] 


















BAS-G, (scale 0-10) 3.4 (2.1) [0 - 7] 
BASDAI‡, (scale 0-10)  3.4 (2.0) [0 - 7.9] 
BASFI, (scale 0-10) 3.4 (2.4) [0 - 8.4] 
Results are presented as mean (SD); [min-max] unless otherwise stated.  281 
* Median (IRQ)  282 
† BASMILin values from initial assessment. BASMILin component results are item values on a 1-10 scale. The higher 283 
the BASMILin score, the more severe the individual's limitation of movement. 284 
‡ BASDAI not completed by n=1 participant  285 
Abbreviations – BAS-G: Bath Ankylosing Spondylitis Global Score; BASDAI: Bath Ankylosing Spondylitis 286 
Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMILin: Bath Ankylosing 287 
Spondylitis Metrology Index (linear version); BMI: body mass index. 288 
3.2. Protocol Fidelity 289 
Thirty-six participants completed the study as per full protocol. One participant completed 290 
supervised testing but did not participate in the unsupervised laboratory testing or the ambulatory 291 
phase of testing due to a flare-up of leg pain. Technical issues affected three ambulatory test sessions; 292 
one sensor malfunctioned, one sensor fell off and was incorrectly re-positioned by the participant, 293 
and one recorder had insufficient battery for data collection. In all of these cases, the data was lost. 294 
During the unsupervised conditions, five participants performed an incorrect number of movement 295 
repetitions and one participant did not perform the movements bilaterally. Two participants did not 296 
consistently use the event button to record the start and end of a movement; this made identification 297 
of the tests difficult for the data analyst, as their movement was restricted and no clear movement 298 
sequence could be identified from the raw data. 299 
3.3. Spinal Mobility Data 300 
The ‘full-arc’ ROM of each measurement using the IMU sensors are summarized in Table 3. The 301 
normalized indices for each measurement, the BASMILin and the composite IMU-ASMI (Amb) scores 302 
are summarized in Table 4. 303 
Table 3. Range of movement of participants measured by IMU sensors 304 
Method Movement 
Day 1 – 
Supervised* 





Day 2 – 
Supervised* 
Day 2 – 
Unsupervise
d† 
Trunk IMU Flexion-Extension 125.7 (27.1) 121.0 (27.2) 120.1 (27.4) 123.7 (25.6) 121.4 (26.4) 
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Ambulatory and Day 2 sessions were 3.0 (1.8 to 6.0), 4.0 319 
(2.0 to 6.3), and 3.0 (1.0 to 5.0), respectively. There was a 320 
statistically significant reduction in fatigue score on Day 321 
2 compared to the ambulatory session (Z = 3.0567, p = 322 
0.0022). No statistically significant differences in fatigue 323 
NRS scores were observed between Day 1 and 324 
ambulatory (Z = -1.20, p = 0.23) or Day 2 sessions 325 
(between Z = 1.20, p = 0.1192). No statistically significant 326 
effect of test session on pain NRS scores was observed, 327 
χ2 (2) = 0.1538, p = 0.86. Median (IQR) pain NRS scores 328 
for Day 1, Ambulatory and Day 2 sessions were 2.0 (1.0 329 
to 3.3), 2.0 (0.8 to 3.0), and 2.0 (0.0 to 3.0), respectively.  ¶330 
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Lateral flexion L+R 46.8 (19.7) 45.4 (17.8) 43.9 (18.2) 47.1 (19.8) 45.5 (19.0) 
Rotation L+R 42.1 (22.2) - - 42.2 (22.4) - 
Lumbar 
region IMU 
Flexion-Extension 60.9 (27.0) 58.6 (26.2) 57.8 (25.4) 58.2 (26.4) 56.6 (24.9) 
Lateral flexion L+R 35.4 (19.1) 34.3 (19.2) 33.6 (19.1) 35.4 (19.2) 34.4 (19.0) 
Rotation L+R 27.1 (16.1) - - 26.8 (15.9) - 
Figures presented as mean (SD). All movements in degrees (°). *n = 40; †n = 39; ‡n = 36 332 
Trunk IMU: the orientation angle from the upper lumbar sensor to the ground; represents lumbar and pelvic 333 
movement. Lumbar region IMU: the angle between the upper lumbar sensor and the sacral sensor; represents 334 
lumbar movement. Output for rotation movements was only available under supervised conditions owing to 335 
technical limitations with the system. 336 
Table 4 Normalized indices for each IMU movement and composite IMU-ASMI (Amb) score per 337 
IMU region 338 
Method Movement 
Day 1 – 
Supervised* 
Day 1 – 
Unsupervised† 
Ambulatory‡ 
Day 2 – 
Supervised* 






2.2 (2.0) 2.6 (2.0) 2.7 (2.0) 2.3 (2.0) 2.5 (2.1) 
Lateral flexion 
L+R 
4.0 (2.7) 4.2 (2.4) 4.4 (2.5) 4.0 (2.7) 4.2 (2.6) 
Rotation L+R 3.4 (3.2) - - 3.4 (3.2) - 
Trunk-ASMI 
(Amb) 






2.5 (2.9) 2.6 (3.0) 2.7 (2.9) 2.7 (3.1) 2.8 (3.0) 
Lateral flexion 
L+R 
4.1 (3.3) 4.3 (3.3) 4.4 (3.3) 4.1 (3.3) 4.3 (3.2) 
Rotation L+R 3.1 (3.3) - - 3.0 (3.2) - 
Lumbar-ASMI 
(Amb) 
3.2 (2.8) 3.5 (3.0) 3.5 (3.0) 3.2 (2.9) 3.5 (3.0) 
BASMILin Total score 3.8 (1.8) - - 3.8 (1.8) - 
Figures presented as mean (SD). *n = 40; †n = 39; ‡n = 36 339 
Trunk IMU: the orientation angle from the upper lumbar sensor to the ground; represents lumbar and pelvic 340 
movement. Lumbar region IMU: the angle between the upper lumbar sensor and the sacral sensor; represents 341 
lumbar movement. Output for rotation movements was only available under supervised conditions owing to 342 
technical limitations with the system. 343 
Abbreviations – BASMILin: Bath Ankylosing Spondylitis Metrology Index (linear version) 344 
3.4. Reliability and Agreement of IMU Movements 345 
The test-retest reliability results for IMU movement tests performed in the laboratory are 346 
summarized in Table 5. Both the Trunk IMU and Lumbar region IMU showed good to excellent 347 
agreement for all movements. The SEM ranged from 5.12° to 9.02° for Flexion + Extension, 2.12° to 348 
4.86° for Lateral flexion, and 5.98° to 8.19° for Rotation (see Supplemental Table 1). Test-retest 349 
reliability and agreement of IMU movement tests performed on different days are available in 350 
Supplemental Table 2.  351 
The reliability and agreement analyses of IMU movement tests performed under laboratory and 352 
ambulatory conditions are summarized in Table 6. Both the Trunk IMU and Lumbar region IMU 353 
showed good to excellent agreement for all movements. The SEM ranged from 4.67° to 8.54° for 354 
Flexion + Extension and 2.17° to 5.39° for lateral flexion. 355 
Deleted: IMU-ASMI356 
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Table 5. Test-retest reliability and agreement of full-arc movement measurements and composite –ASMI (Amb) scores under supervised and unsupervised conditions in 357 
the laboratory 358 
 




95% LOA ICC 
[95% CI] 
SEM 
95% LOA ICC 
[95% CI] 
SEM 










6.98 2.0 -16.7 20.6 
0.93 
[0.88-0.96] 
7.20 -0.3 -19.5 18.8 
0.96 
[0.84-0.98] 
5.45 4.7 -7.6 17.1 
0.94 
[0.90-0.97] 





3.95 -0.3 -11.4 10.8 
0.95 
[0.91-0.97] 
3.99 -0.0 -11.5 11.4 
0.94 
[0.89-0.97] 
4.86 2.5 -18.6 23.7 
0.97 
[0.94-0.98] 





0.56 -0.0 -1.6 1.5 
0.96 
[0.94-0.98] 
0.42 0.0 -1.15 1.22 
0.91 
[0.84-0.95] 
0.68 -0.2 -2.0 1.5 
0.93 
[0.86-0.96] 
0.62 -0.1 -1.9 1.6 





9.02 2.7 -21.8 27.2 
0.89 
[0.80-0.94] 
8.70 2.0 -21.4 25.4 
0.96 
[0.93-0.98] 
5.12 3.8 -28.4 35.9 
0.98 
[0.97-0.99] 





2.84 -0.1 -8.1 7.9 
0.97 
[0.95-0.99] 
3.32 -0.1 -8.6 8.5 
0.98 
[0.97-0.99] 
2.45 0.7 -6.1 7.5 
0.99 
[0.98-0.99] 





0.63 -0.0 -1.9 1.8 
0.96 
[0.93-0.98] 
0.60 -0.1 -1.64 1.50 
0.96 
[0.92-0.98] 
0.57 -0.3 -1.9 1.4 
0.96 
[0.92-0.98] 
0.57 -0.3 -1.9 1.4 
All ICC results were statistically significant, p<0.001.  Bold denotes ICC >0.9. *n = 40; †n = 39 359 
Abbreviations - ICC: Intraclass correlation coefficient; SEM: standard error of measurement (deg); 95% LOA: 95% limits of agreements (deg) 360 
361 
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Table 6. Test-retest reliability and agreement of full-arc movement measurements and composite –ASMI (Amb) scores under laboratory and ambulatory conditions. 363 
 




95% LOA ICC 
[95% CI] 
SEM 
95% LOA ICC 
[95% CI] 
SEM 










6.56 6.9 -6.1 19.9 
0.97 
[0.94-0.98] 
4.67 2.3 -10.0 14.6 
0.89 
[0.78-0.94] 
8.54 4.7 -18.6 28.0 
0.92 
[0.85-96] 





4.95 7.3 -19.4 34.1 
0.96 
[0.93-0.98] 
3.31 4.8 -18.1 27.7 
0.93 
[0.81-0.97] 
5.39 7.6 -18.8 34.0 
0.97 
[0.93-0.98] 





0.68 -0.4 -2.1 1.3 
0.97 
[0.94-0.99] 
0.36 -0.2 -1.1 0.6 
0.89 
[0.78-0.94] 
0.77 -0.3 -2.4 1.7 
0.97 
[0.93-0.98] 
0.39 -0.2 -1.2 0.7 





7.18 3.6 -14.7 21.8 
0.92 
[0.85-0.96] 
7.52 2.1 -18.2 22.5 
0.93 
[0.87-0.96] 
6.82 0.5 -18.3 19.2 
0.93 
[0.88-0.97] 





2.73 2.0 -4.6 8.7 
0.98 
[0.97-0.99] 
2.33 1.2 -4.9 7.4 
0.97 
[0.93-0.98] 
3.43 2.1 -6.8 10.9 
0.98 
[0.96-0.99] 





0.69 -0.4 -2.2 1.4 
0.97 
[0.93-0.98] 
0.52 -0.2 -1.7 1.3 
0.95 
[0.90-0.97] 
0.64 -0.3 -2.0 1.5 
0.98 
[0.97-0.99] 
0.43 -0.1 -1.1 1.0 
All ICC results were statistically significant, p<0.001. n = 36 364 
Abbreviations - ICC: Intraclass correlation coefficient; SEM: standard error of measurement (deg); 95% LOA: 95% limits of agreements (deg)365 
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3.5. Reliability and Agreement of IMU-ASMI (Amb) indices 367 
The reliability and agreement analyses of IMU-ASMI (Amb) scores are summarized in Table 5 and 368 
Table 6. Both the Trunk-ASMI (Amb) and Lumbar-ASMI (Amb) showed strong agreement under 369 
laboratory and ambulatory conditions. The SEM ranged from 0.36 to 0.77 for Trunk-ASMI (Amb) and 370 
0.43 to 0.69 for Lumbar-ASMI (Amb). The IMU-ASMI (Amb) scores showed good correlation with 371 
BASMILin under all test conditions (see Table 7). Pearson correlations were ≥ 0.85. 372 
Table 7 Pearson Correlations between BASMILin and IMU-ASMI (Amb) scores under laboratory and 373 




BASMILin Day 2 
Trunk-ASMI (Amb) 
Supervised Day 1 0.85 0.87 
Supervised Day 2 0.85 0.88 
Unsupervised Day 1 0.85 0.88 
Unsupervised Day 2 0.86 0.91 
Ambulatory 0.88 0.91 
Lumbar-ASMI 
(Amb) 
Supervised Day 1 0.86 0.88 
Supervised Day 2 0.86 0.86 
Unsupervised Day 1 0.86 0.88 
Unsupervised Day 2 0.86 0.90 
Ambulatory 0.87 0.89 
Abbreviations – BASMILin: Bath Ankylosing Spondylitis Metrology Index (linear version) 375 
3.6 Pain and Fatigue Monitoring  376 
Thirty-three participants completed self-report pain and fatigue NRS during all three test 377 
sessions (Day 1, Ambulatory, Day 2). There was a statistically significant difference in fatigue NRS 378 
scores depending on test session, χ2(2) = 8.6154, p < 0.001. Post-hoc analysis with Wilcoxon signed-379 
rank test was conducted with a Bonferroni-adjusted significance level set at p < 0.017. Median (IQR) 380 
fatigue NRS scores for Day 1, Ambulatory and Day 2 sessions were 3.0 (1.8 to 6.0), 4.0 (2.0 to 6.3), and 381 
3.0 (1.0 to 5.0), respectively. There was a statistically significant reduction in fatigue score on Day 2 382 
compared to the ambulatory session (Z = 3.0567, p = 0.0022). No statistically significant differences in 383 
fatigue NRS scores were observed between Day 1 and ambulatory (Z = -1.20, p = 0.23) or Day 2 384 
sessions (between Z = 1.20, p = 0.1192). No statistically significant effect of test session on pain NRS 385 
scores was observed, χ2 (2) = 0.1538, p = 0.86. Median (IQR) pain NRS scores for Day 1, Ambulatory 386 
and Day 2 sessions were 2.0 (1.0 to 3.3), 2.0 (0.8 to 3.0), and 2.0 (0.0 to 3.0), respectively.   387 
4. Discussion 388 
This study demonstrates the reliability of an IMU sensor-based system for measuring spinal 389 
range of motion of individuals with axSpA. The IMU sensor-based system showed good to excellent 390 
test-retest reliability under supervised and unsupervised conditions in the laboratory setting, and 391 
unsupervised in the home setting.  392 
Composite IMU-ASMI (Amb) scores were calculated for the lumbopelvic region (Trunk-ASMI) 393 
and the lumbar region (Lumbar-ASMI) based on methods used in previous studies [19, 26]. In this 394 
study, rotation movement data was only included in the supervised IMU-ASMI (Amb) scores due to 395 
technical limitations within the system. As rotation has a smaller range of movement in the lumbar 396 
spine than movement in the other two planes, this limitation was hypothesized to have been of 397 
negligible practical consequence [30-32]. Reliability of composite IMU-ASMI (Amb) scores was 398 
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conditions similar to previously reported scores in a similar cohort [19]. Reliability of composite IMU-408 
ASMI (Amb) scores was also found to be excellent in unsupervised ambulatory settings; an 409 
unsupervised IMU-ASMI (Amb) score could therefore function as a reliable surrogate for a 410 
supervised IMU-ASMI score. 411 
The limits of agreement showed greater full-arc range of motion and lower IMU-ASMI (Amb) 412 
scores (better performance) when participants were supervised than when unsupervised, suggestive 413 
of a small systematic bias. Participants may have tried harder when under direct observation than 414 
when unsupervised, due to beliefs about researcher expectations and social desirability [33]. 415 
Participants may also be more likely to perform movements slightly ‘off-plane’ or with less accuracy 416 
when performing the movements unsupervised, resulting in reduced range of motion being 417 
recorded. Circadian rhythm of symptoms in axSpA may have influenced the performance of spinal 418 
movement tasks, however, pain and fatigue symptoms were shown to be largely stable across test 419 
sessions.   420 
A secondary aim of the study was to evaluate the reliability of an IMU-ASMI (Amb) score and 421 
to determine correlation with conventional metrology. Both supervised and unsupervised IMU-422 
ASMI (Amb) scores showed strong correlations with BASMILin and may be a suitable proxy for 423 
conventional metrology when direct measurement by a clinician is not possible. A limitation of the 424 
IMU-ASMI (Amb) scores described is they do not include measures of standing posture, hip or neck 425 
range of motion. As a result, they should not be considered a substitute for conventional BASMI. 426 
Including these additional components would require additional IMU sensors, and longer set-up and 427 
test protocol time and was beyond the scope of this study. Despite this limitation, the IMU-ASMI 428 
(Amb) gives a comprehensive and accurate representation of spinal movement in degrees across 429 
three planes of movement 430 
This study supports the concept that individuals with axSpA can use an IMU sensor-based 431 
system to monitor their spinal mobility reliably and accurately, without supervision at home or in 432 
non-clinical settings. While this would not replace supervised tests in a clinical setting, it offers 433 
clinicians a reliable method of remotely monitoring spinal mobility in individuals with axSpA. This 434 
is an important step in developing a system that will allow clinicians and researchers to track small 435 
changes in spinal mobility over time, and measure the impact of exercise programs, without 436 
necessitating frequent, in-person consultations. The increase in remote telehealth consultations, 437 
accelerated by the SARS-CoV-2 pandemic, is broadly supported by patients and clinicians [12, 34-36]. 438 
However, the inability to conduct a physical examination of spinal mobility has presented a persistent 439 
obstacle to the adoption of remote consultations [35, 37]. IMU sensor-based systems could provide a 440 
solution by facilitating reliable and accurate measurement of spinal metrology.  441 
eHealth and mobile-based applications have been recognized as potential ways of improving 442 
remote monitoring. Mobile health (mHealth) can contribute to the empowerment of patients, who 443 
could manage their health more actively and live more independently thanks to self-assessment or 444 
remote monitoring solutions, and support healthcare professionals in treating patients more 445 
efficiently [38]. Most studies to date examining eHealth and mHealth in rheumatology have focused 446 
on rheumatoid arthritis [39-40]. Recent systematic reviews have identified approximately 35 apps 447 
currently available that offer symptom tracking, educational information and links to online 448 
communities for people with rheumatic and musculoskeletal disease [41-43]. However, only one app 449 
was specific to axSpA [44]. Future development of an IMU sensor-based system linked to a mobile 450 
application could enhance the utility and specificity of such an application in relation to axSpA, 451 
where monitoring of spinal range of motion is an important indicator of disease progression [45-46].  452 
In addition to providing data to a clinician, the output of the IMU sensor-based system could 453 
support self-management interventions [47-50]. IMU-ASMI (Amb) scores, expressed on a scale of 0 454 
to 10, are easy to interpret without knowledge of the normal ranges of each spinal movement. This 455 
could be used by people with axSpA as a motivational point to encourage adherence to exercise or 456 
pharmaceutical treatments and facilitate self-monitoring during maintenance phases or disease 457 
flares. It is a strength of the study that a broad cross-section of individuals with axSpA participated, 458 
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completed the simple test movements unsupervised by following simple standardized instructions, 483 
either by video or written instructions; just ten percent of participants failed to complete the study 484 
protocol in full, demonstrating the feasibility.   485 
One participant did not complete the ambulatory phase testing as a sensor detached from the 486 
skin, and they were unable to reposition it themselves. This illustrates a limitation of the current 487 
sensor setup, with participants unable to self-attach sensors with the degree of precision required. In 488 
this study sensors were attached by a trained member of the research team, however, if this is to be 489 
adopted as a self- or remote-monitoring tool, an alternate way of attaching sensors is required. This 490 
study used a two-sensor setup, however, a single sensor set-up warrants further investigation; results 491 
from the Trunk IMU (positioned at L1 vertebra) showed equivalent reliability to the results from the 492 
two sensor Lumbar region IMU setup. Finally, unlike conventional metrology measures, the sensor 493 
set-up used in this study does not include measures of cervical mobility. However, the correlation 494 
between mean –ASMI (Amb) versus mean BASMILin was 0.82, which suggests that the IMU–ASMI 495 
(Amb) is a clinically relevant measure, despite not including the cervical region. Furthermore, it has 496 
been previously shown that removing cervical mobility tests does not affect the reliability of the IMU-497 
ASMI [19].  498 
Currently, standard clinical tests of spinal movement in individuals with axSpA focus on 499 
movements in a single plane. IMU sensor systems offer the potential for measuring multi-planar 500 
spinal movements that would be closer to ‘real-world’ movements; as well as providing the 501 
additional benefit of monitoring and attaining data over longer periods than that of a clinic-based 502 
assessment.  Future research should seek to establish the validity and reliability of an IMU sensor-503 
based system to measure spinal mobility during functional movement tests. More performance-based 504 
tests may be of more interest to both the clinician and the patient and may be a more objective 505 
measure of function instead of pure mobility.  506 
5. Conclusions 507 
This study has demonstrated that an IMU sensor-based system is a reliable way of measuring 508 
spinal mobility in axSpA under supervised and unsupervised conditions. While not a replacement 509 
for established clinical measures, composite IMU-ASMI (Amb) scores may be reliably used as a proxy 510 
measure of spinal mobility.   511 
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Appendix A 539 
Supplemental Table 1. Test-retest reliability and agreement of full-arc rotation measurements 540 
between IMU sensors under supervised conditions in the laboratory 541 
 
Supervised Day 1 v Supervised Day 2 
ICC [95% CI] SEM 
95% LOA 
Bias Lwr Upr 
Rotation L+R 
Trunk IMU 0.86 [0.76-0.93] 8.19 -0.2 -23.2 22.9 
Lumbar region IMU 0.86 [0.75-0.92] 5.98 0.3 -16.3 16.9 
n = 40. All ICC results were statistically significant, p<0.001.  542 
Abbreviations - ICC: Intraclass correlation coefficient; SEM: standard error of measurement (deg); 95% 543 
LOA: 95% limits of agreements (deg) 544 
Supplemental Table 2. Test-retest reliability and agreement of full-arc movement measurements 545 
and composite -ASMI scores under supervised and unsupervised conditions on different days in the 546 
laboratory 547 
 














7.31 4.4 -14.1 22.9 
0.91 
[0.84-0.95] 





4.28 2.5 -17.9 23.0 
0.92 
[0.85-0.96] 




0.64 -0.2 -1.9 1.6 
0.88 
[0.78-0.93] 
0.72 0.2 -2.0 2.3 





8.37 3.4 -18.1 24.9 
0.87 
[0.76-0.93] 





2.92 0.6 -7.5 8.7 
0.96 
[0.93-0.98] 





0.69 -0.3 -2.2 1.5 
0.92 
[0.85-0.96] 
0.85 0.2 -2.1 2.5 
 
n = 39. All ICC results were statistically significant, p<0.001. Bold denotes ICC >0.9.  548 
Abbreviations - ICC: Intraclass correlation coefficient; SEM: standard error of measurement (deg); 95% LOA: 549 
95% limits of agreements (deg)  550 
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